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Infection with Group B Streptococcus (GBS) is considered an important public health 
problem. It is associated with: Neonatal sepsis, meningitis, pneumonia, neonatal death, 
septic abortion, chorioamnionitis, endometritis and other perinatal infections. The aim of 
this study was to determine the best screening strategy for GBS in pregnant women. For 
this a systematic review and meta-analysis were carried out in the Nursing Department of 
the Federal University of São Paulo, Cochrane Center, Brazil. Sources used were, EMBASE, 
LILACS, Medline, list of references, personal communication and the Cochrane library. The 
criterion for the selection of the studies was; studies which analyze some type of screening 
for GBS in pregnant women. Independent of the comparator, all analyses were in favor of 
a universal screening program for reducing the incidence of neonatal sepsis. The evidence 
obtained in this study suggests that the strategy of universal screening of pregnant women 
associated with the use of prophylactic antibiotics is safe and effective.
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Rastreamento de Streptococcus do grupo B em gestantes: revisão 
sistemática e metanálise
A infecção por Streptococcus do grupo B (GBS) é considerada importante problema 
de saúde pública. Está associada à sepse neonatal, meningite, pneumonia, óbito 
neonatal, aborto séptico, coriomnionite, endometrite e outras infecções perinatais. O 
objetivo deste estudo foi determinar a melhor estratégia de rastreamento de GBS em 
gestantes. Como método usou-se a revisão sistemática com metanálise. A pesquisa foi 
realizada no Departamento de Enfermagem/Universidade Federal de São Paulo/Centro 
Cochrane do Brasil. Para a busca usaram-se as fontes Embase, LILACS, MEDLINE, lista 
de referências bibliográficas, comunicação pessoal e Cochrane Library. Usaram-se, como 
critério de seleção, os estudos que analisaram algum tipo de rastreamento para GBS em 
gestantes. Independente do comparador, os resultados apontam que todas as análises 
foram favoráveis ao programa de screening universal para a redução da incidência de 
sepse neonatal. Pode-se concluir que evidências obtidas no estudo são sugestivas de que 
a estratégia de screening universal para as gestantes, associada ao uso de antibiótico 
profilático, é segura e efetiva.
Descritores: Gestantes; Streptococcus agalactiae; Metanálise.
Rastreo de Streptococcus del grupo B en gestantes: revisión sistemática 
y metanálisis
La infección por Streptococcus del grupo B (GBS) es considerada un importante problema 
de salud pública. Los estreptococos están asociados a: sepsis neonatal, meningitis, 
neumonía, muerte neonatal, aborto séptico, corioamnionitis, endometritis y otras 
infecciones perinatales. El objetico del estudio fue determinar la mejor estrategia de 
rastreo de GBS en gestantes. Se trata de una revisión Sistemática con Metanálisis. 
Fue realizada en el Departamento de Enfermería de la Universidad Federal de Sao 
Paulo, Centro Cochrane de Brasil. Se utilizaron las siguientes fuentes: EMBASE, LILACS, 
Medline, lista de referencias bibliográficas, comunicación personal y Cochrane Library. 
Como criterio para la selección de los estudios, se escogieron los que analizaron algún 
tipo de rastreo para GBS en gestantes. Independientemente del comparador, todos los 
análisis fueron favorables al programa de screening universal para la reducción de la 
incidencia de sepsis neonatal. Las evidencias obtenidas en el estudio sugieren que la 
estrategia de screening universal para las gestantes asociado al uso de antibióticos 
profilácticos es segura y efectiva.
Descriptores: Mujeres Embarazadas; Streptococcus agalactiae; Metanálisis.
Introduction
Streptococcus agalactiae or group B Streptococcus 
(GBS) was more important for veterinary medicine in 
the past, as the causal pathogen for bovine mastitis, 
however, in 1938 GBS was identified as a human 
pathogen, related to three fatal cases of puerperal 
sepsis(1). With the first published study of perinatal GBS 
infection, the relationship of the bacteria with negative 
maternal and neonatal outcomes became clear and 
its importance in diseases related to human beings 
was recognized, especially in the perinatal period(2). 
It is currently considered a serious infection, being 
one of the major causes of meningitis, pneumonia, 
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neonatal sepsis, neonatal death, septic abortion, 
chorioamnionitis, endometritis, pyelonephritis, 
cellulitis, puerperal sepsis, and premature rupture 
of membranes, among other perinatal infections(3-5). 
This problem aroused the interest of health authorities 
so that, in 1996, the Center for Disease Control 
(CDC) published a report concerning standards and 
recommendations, from the public health perspective, 
for prevention of perinatal diseases caused by 
Streptococcus agalactiae with support from the 
American College of Obstetricians and Gynecologists, 
the American Academy of Pediatrics and other 
agencies(3). In the guidelines two alternatives are 
suggested for prophylaxis in intrapartum pregnant 
women for the prevention of early neonatal infection 
by GBS. One based on the results of cultures of vaginal 
and anorectal content collected in the third trimester 
of pregnancy and the other based on the risk factors 
presented by the pregnant woman. The risk factors 
described are: Preterm labor <37 weeks of gestation, 
prior GBS bacteriuria, fever, prolonged rupture of 
membrane ≥18 hours, and the reporting of neonatal 
infection in previous a birth.
The guidelines were revised in 2002 and underwent 
some modifications based on evidence reported in 
some cases where vertical infection by GBS was 
detected where the pregnant woman did not present 
risk factors(4). The latest update, of 2010, is based on 
the existing evidence of perinatal GBS prevention and 
reinforces the universal screening recommendations 
in the third trimester of pregnancy, standardizes the 
laboratory methods for detection of GBS, changes 
the dose of antimicrobial prophylaxis and updates 
the recommendations for premature infants and 
neonates at risk of early infection(5). The main measure 
for the prevention of neonatal infection by group B 
Streptococcus is to identify and to prophylactically 
treat pregnant women, avoiding postpartum problems 
and early neonatal infection(6-7).
There is intense debate concerning prevention 
strategies for perinatal GBS, with regard to the 
feasibility and impact of the protocols suggested by the 
CDC (based on risk factors or the universal screening 
of pregnant women), so that many countries still do 
not have defined policies to remedy the problem. The 
principle aim of this study is to identify the best strategy 
for prenatal screening for prevention of perinatal 
infection caused by GBS, having as the main premise 
to analyze the best strategy to identify pregnant women 
infected/colonized by this bacterium who should be 
submitted to intrapartum prophylaxis, thus being more 
effective in reducing the incidence of neonatal sepsis. 
Motivated by the importance of the infection in the public 
health context, lack of standardization of preventive 
strategies and doubts about their effectiveness, this 
Systematic Review and Meta-analysis was performed 
in an unprecedented manner with support from the 
Department of Nursing / UNIFESP and the Cochrane 
Centre of Brazil. 
Method
This Systematic Review and Meta-analysis followed 
the steps proposed by the Cochrane Collaboration(8). 
Studies were included regardless of language or form of 
publication. As inclusion criterion, in this Meta-analysis 
it was necessary for the studies to present at least the 
primary outcome: Incidence of early neonatal sepsis, 
with the participants being pregnant women evaluated 
in the last trimester of pregnancy. The interventions 
compared for Meta-analysis were: screening based 
on maternal risk factors, universal screening or no 
preventive intervention for GBS. The exclusion criteria 
were studies that did not evaluate outcomes relevant to 
the study or which selected pregnant women in the first 
two trimesters of pregnancy.
Strategies for identification of the studies
The relevant studies were identified through 
electronic search of the Cochrane Library database, 
including the databases Cochrane Controlled Trials 
Register contained in the Cochrane Library 2010, 
volume 10, PUBMED (January 1966 to Jan 2010), 
EMBASE (January1985 to Jan 2010), LILACS (January 
1982 to Jan 2010), and SciELO (June 1998 to Jan 2010): 
www.controlledtrials.com, abstracts of work presented 
at conferences, published and identified references of 
review articles and of systematic reviews and identified 
references of randomized clinical trials. The main 
descriptors used in the search strategy were: “Mass 
Screening” OR “Neonatal Screening” OR screening AND 
Streptococcus group B OR Streptococcus agalactiae
Selection of the studies
The studies were read by two independent 
reviewers (MT) and (HS) in order to ascertain whether 
they met the inclusion criteria. The evaluation, by the 
reviewers, of the titles and abstracts of all identified 
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1477 studies identified 
in the search
97 studies selected
only eight studies met the 
inclusion criteria for the study
1380 studies were excluded after 
reading of title and/or abstract
Figure 1 - Flowchart of the selection and identification of the studies
Title Author(s) Year / Country Study design Interventions Outcomes STROBE
Neonatal Group B 
Streptococcal Sepsis during 
two years of a universal 
screening program
Gibbs RS, McDuffie 
RS, Jr, McNabb F, 
Fryer GE, Miyoshi T, 
Merenstein G.
1994 / USA Retrospective 
cohort 
Universal screening 
versus no 
intervention
Incidence of neonatal 
sepsis
Experimental = 5/4843
Control =  10/6667 
A
Group B streptococci during 
pregnancy: A comparison of 
two screening and treatment 
protocols.
Hafner E, Sterniste 
W, Rosen A, 
Schuchter K, Plattner 
M,et al.
1998/ 
Austria
Prospective 
cohort
Universal screening 
versus risk factor 
based screening 
Incidence of neonatal 
sepsis
Experimental = 0/3952
Control = 20/3700 
A
studies were not blind and complete copies of all the 
relevant articles were made available. In case of doubt 
or disagreement, a third reviewer (DAB) was asked to 
give an opinion regarding whether the study should be 
included or not.
Evaluation of the methodological quality
The methodological quality was defined as the 
confidence that the design and reporting of the study 
were free from bias(9). Two independent reviewers used 
the STROBE (strengthening the reporting of observational 
studies in epidemiology) recommendations(10). Based on 
the STROBE recommendations, the evaluation of this 
meta-analysis was divided into three categories: A - in 
the cases of the studies that fulfill 80% or more of the 
criteria; B - in the cases of compliance with between 80% 
and 50% of the criteria; and C - if there was less than 50% 
compliance with the criteria established by STROBE. 
Data extraction and statistical analysis
The studies were initially stratified according 
to the type of design and then in relation to the 
outcomes, following the Cochrane methodology(8). 
Review Manager 5(11), provided by The Cochrane 
Collaboration, was used for the statistical analysis. 
For dichotomous variables, the odds ratio (OR) with a 
respective confidence interval of 95% was calculated 
by the fixed and random model. For the calculation of 
heterogeneity the Mantael-Haenzel chi-square and the 
I2 were used.
Results
After an extensive literature search 1477 
studies were found, as follows: 1421 Pubmed, 39 
Embase, seven Lilacs and 10 manual searches of 
the references of studies. In a pre-selection 97 
studies were identified by the reviewer (MT) and 
93 by the other reviewer (HS). The disagreements 
were resolved by a third reviewer (DA), decided by 
reading in full the 97 articles selected, as shown in 
Figure 1.
Finally, eight studies were included in this review: 
Gibbs et al.(12),  Hafner et al.(13); Jeffrey et al.(14); Main 
et al.(15); Reisner et al.(16); Vergani et al.(17); Puopolo et 
al.(18); Renner et al.(19), as described in Figure 2.
(Figure 2 continue in the next page...)
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Title Author(s) Year / Country Study design Interventions Outcomes STROBE
Eight-year outcome of universal 
screening and intrapartum 
antibiotics for maternal group B 
Streptococcus carriers.
Jeffrey HE, Lahra 
MM.
1998 / 
Austrialia
Prospective 
cohort
Universal screening 
versus no 
intervention
Incidence of neonatal 
sepsis:
Experimental = 8/36342
Control = 8/5732
A
Prevention of early-onset 
invasive neonatal group B 
streptococcal disease in a 
private hospital setting: the 
superiority of culture-based 
protocols.
Main EK, Slagle T. 2000 / USA Prospective 
cohort
Universal screening 
versus risk factor 
based screening 
Incidence of neonatal 
sepsis:
Experimental =  0/9304
Control = 15/13270
A
Performance of a group B 
streptococcal prophilaxis 
protocol combining high-
risk treatment and low-risk 
screening.
Reisner DP, Haas 
MJ, Zingheim RW, 
Williams MA, Luthy 
DA
2000 / USA Prospective 
cohort
Universal screening 
versus risk factor 
based screening 
Incidence of neonatal 
sepsis
Experimental = 2/9932
Control = 9/8188 
B
Impact of different prevention 
strategies on neonatal group B 
streptococcal disease.
Vergani P, Patanè L, 
Colombo C, Borroni 
C, Giltri G, Ghidini 
A et al.
2002 / Italy Retrospective 
cohort 
Universal screening 
versus risk factor 
based screening 
Incidence of neonatal 
sepsis: Experimental = 
0.4/1000
Control = 0.8/1000 
B
Early-onset group B 
streptococcal disease in the 
maternal screening.
Puopolo KM, Madoff 
LC, Eichenwald EC.
2005 / USA Retrospective 
cohort 
(10 years)
Universal screening 
versus risk factor 
based screening 
Incidence of neonatal 
sepsis
Experimental = 0.37/1000
Control = 1.1/1000 
B
Efficacy of a strategy to prevent 
neonatal early-onset group B 
streptococcus (GBS) sepsis.
Renner RM, Renner 
A, Schmid S, Hoesli 
I, Nars P, Holzgreve 
W.
2006 / 
Switzerland
Retrospective 
cohort 
(12 years)
Universal screening 
versus no 
intervention
Incidence of neonatal 
sepsis:
Experimental = 0.53/1000
Control = 1/1000 
A
 (continuation)
The studies included in Figures 3 and 4 addressed 
the incidence of neonatal sepsis caused by GBS; the 
figures are divided by type of intervention and design. 
The study by Jeffrey et al.(14) of a prospective nature 
showed an incidence of sepsis of 0.2/1000 births for 
those patients who followed the universal screening 
protocol and of 1.4/1000 births for the risk factors 
based screening group. Regarding the retrospective 
cohort studies included in Figure 2, the incidence of each 
study were: Gibbs et al.(12) 1/1000 births; Vergani et 
al.(17) 0.4/1000 births; Renner et al.(19) 0.5/1000 births 
for the groups of patients who underwent universal 
screening. The incidence of sepsis in the groups without 
preventive intervention (no screening) were: Gibbs et 
al.(12) 1.5/1000 births; Vergani et al.(17) 0.9/1000 births; 
Renner et al.(19) 1/1000 births.
For the evaluation of the incidence of neonatal 
sepsis in Figure 2, four studies were included comparing 
universal screening with no screening, having n=64324 
in the intervention group and n=37098 in the control 
group. The data show significant differences between the 
comparison groups, with a higher proportion of patients 
benefiting from universal screening, compared with the 
control group (no screening), with odds ratio of 0.43 
(95% confidence interval of 0.25 to 0.73, p=0.002). It 
was not possible to identify substantial heterogeneity 
(statistically significant) among the included studies 
(I2=39.8%, p=0.17). However, the differences between 
the comparison groups were not statistically significant 
for the retrospective studies, as shown by the confidence 
intervals (horizontal lines) that intersect the line of the 
null hypothesis (vertical line).
Figure 2 - Summary of the characteristics of the included studies
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Review: Strategy for the prevention of early neonatal infections
Comparison: 01 universal screening for the detection of GBS in pregnant women versus the control group of no 
screening
Outcome: 01 Incidence of neonatal sepsis 
Study or Sub-category
Treatment Control OR (fixed) Weight OR (fixed)
n/N n/N 95% CI % 95% CI
01 Prospective studies
Jeffrey HE 1998 8/36342 8/5732 31.52 0.16 [0.06, 0.42]
Subtotal (95% CI) 36342 5732 31.52 0.16 [0.06, 0.42]
Total events 8 (treatment), 8 (control)
Estimate of effect: Z=3.69 (P=0.0002)
02 Retrospective studies
Gibbs RS 1994 5/4843 10/6667 19.17 0.69 [0.24, 2.01]
Vergani 2002 6/13754 8/8573 22.47 0.47 [0.16, 1.35]
Renner 2006 5/9385 16/16126 26.84 0.54 [0.20, 1.47]
Subtotal (95% CI) 27982 31366 68.48 0.56 [0.30, 1.02]
Total events 16 (treatment), 34 (control)
Heterogeneity test: Chi2=0.26, df=2 (P=0.88), I2=0%
Estimate of effect: Z = 1.90 (P = 0.06)
Total (95% IC) 64324 37098 100.00 0.43 [0.25, 0.73]
Total events 24 (treatment), 49 (control) 
Heterogeneity test: Chi2=4.98, df=3 (P=0.17) I2=39.8%
Estimate of effect: Z=3.12 (P=0.002)
10.10.010.001
Favors 
control
Favors 
treatment
10 100 1000
GBS=Group B Streptococcus
OR=Odds Ratio
CI=Confidence interval
n/N=Number of participants that expressed the event / Total number of participants of the group
Figure 3 - Odds ratio for incidence of neonatal sepsis: universal screening versus control (no screening)
Figure 4 shows significant superiority for the 
universal screening group versus the control group 
(risk factor based) when compared to the incidence 
of neonatal sepsis with an odds ratio of 0.22 (95% 
confidence interval of 0.14 to 0.34, p=0.000001). 
Heterogeneity was not identified among the included 
studies (I2=39.3%, p=0.16). 
The methodology of this Systematic Review and 
Meta-analysis rigorously followed the recommendations 
of the Cochrane and the STROBE, the entire process was 
performed by two independent reviewers, the search 
strategy was broad, there was no language restriction, 
and the studies included were evaluated regarding their 
methodological content. All these steps were intended 
to reduce the possibility of biases and to give more 
credibility to the results.
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Review: Strategy for the prevention of early neonatal infections
Comparison:  02 universal screening for the detection of GBS in pregnant women versus the control group of risk 
factor based screening
Outcome: 01 Incidence of neonatal sepsis (intention to treat analysis) 
Study or Sub-category
Treatment Control OR (fixed) Weight OR (fixed)
n/N n/N 95% CI % 95% CI
01 Prospective studies
Hafner 1998 0/3952 20/3700 21.11 0.02 [0.00, 0.38]
Main 2000 0/9304 8/6829 9.77 0.04 [0.00, 0.75]
Reisner 2000 2/9932 9/8188 9.83 0.18 [0.04, 0.85]
Vergani 2002 6/13754 8/10303 9.11 0.56 [0.19, 1.62]
Subtotal (95% CI) 36942 29020 49.83 0.16 [0.08, 0.32]
Total events 8 (treatment), 8 (control)
Heterogeneity test: Chi2=8.22, df=3 (P=0.04), I2=63.5%
Estimate of effect: Z=5.03 (P< 0.00001)
02 Retrospective studies
Puopolo 2005 25/67260 38/34262 50.17 0.33 [0.20, 0.55]
Subtotal (95% CI) 67260 34262 50.17 0.33 [0.20, 0.55]
Total events 25 (treatment), 38 (control) 
Estimate of effect: Z=4.25 (P<0.0001)
Total (95% IC) 104202 63282 100.00 0.25 [0.16, 0.37]
Total events 33 (treatment), 83 (control) 
Heterogeneity test: Chi2=8.10, df=4 (P=0.09) I2=50.6%
Estimate of effect: Z = 6.74 (P < 0.00001)
GBS=Group B Streptococcus
OR=Odds Ratio
CI=Confidence interval
n/N=Number of participants that expressed the event / Total number of participants of the group
Figure 4 - Odds ratio for incidence of neonatal sepsis (analysis by protocol): Universal screening versus control group 
with risk factor based screening
10.10.010.001
Favors 
control
Favors 
treatment
10 100 1000
Discussion
Data found in a large study that evaluated the impact 
of the implementation of the two CDC guidelines of 1996, 
based on risk factors, and 2002, suggesting universal 
screening, highlight the decline in the rates of neonatal 
GBS infection of approximately 0.47/1000 births in the 
period 1999 to 2001 to 0.34/1000 in 2004, consolidating 
the strategy of universal screening(20-23). The fatality rate 
in neonates in the 1970’s, a time when GBS had been 
recognized as a human pathogen, was approximately 
50%(4). However, with advances in neonatal care and 
increased use of prophylactic antibiotics, this rate 
decreased to 10-15% in the 1990’s(22-25) and to 5% after 
the introduction of measures of screening, prevention 
and prophylaxis for GBS(5,21).
The impact on the reduction of the incidence of 
GBS in neonates is based on the timely detection of the 
bacteria in pregnant women, at between 35-37 weeks 
of gestation, by vaginal and rectal contents culture. The 
detection interval was stipulated because it is believed 
that colonization/infection may be transient and it is 
relevant to know the colonization/infection status in the 
period just prior to the birth. One study found that the 
predictive value was between 95%-98% for the women 
who were examined up to 5 weeks prior to delivery, but 
for those that were examined with a larger interval there 
was a decline in the predictive value(26). Another extremely 
important factor regarding the reduction of negative 
outcomes in neonates is the administration of intrapartum 
antimicrobial prophylaxis(6). The efficacy of the use of 
penicillin and ampicillin intravenously in the intrapartum 
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period to prevent early neonatal infection caused by GBS 
has been demonstrated in clinical trials(6,27).
Motivated by the relevance of the problem in the 
public health context the Municipal Health Secretariat 
of São Paulo State released a technical note for the 
screening for GBS in all pregnant women included in the 
Mãe Paulistana Program, in which the responsibilities 
are divided between the Primary Healthcare, to identify 
the pathogen at the appropriate time, the Maternity Unit 
to treat the pregnant women and the Neonatologist to 
prevent possible negative outcomes in the neonate(28). 
A recent analysis on the profile of deaths in children 
under one year of age in the municipality of São Paulo 
between 2000-2008, shows that diseases acquired in 
the perinatal period accounted for 57.8% in 2000 and 
55.1% in 2008, this decline may reflect the actions of 
public policies on the prevention of and attention to 
neonatal infection caused by GBS(29). 
Over time many advances have been seen in the 
prevention of this infection, however, there is a need for 
integrated actions for the implementation of screening 
protocols, prophylaxis and monitoring of the incidence of 
sepsis. In a cross-sectional study where the objective was 
to evaluate, by means of indicators established by the 
Ministry of Health(30), the quality of prenatal care offered 
in 12 primary health units of the municipality of São 
Paulo, showed that in the year 2000 none of the services 
analyzed were considered to be Excellent and only 7.7% 
of the services received this indicator in 2004(31). 
Implications for the practice
The evidence obtained in this study suggests that 
the strategy of universal screening for pregnant women 
associated with the use of prophylactic antibiotics is safe 
and effective, as demonstrated by the reductions in the 
incidence of neonatal sepsis.
Implications for research
- National studies to evaluate the magnitude of the 
problem of early neonatal infection caused by GBS in the 
maintenance of the mortality rate in the population;
- Studies which evaluate the impact of the adoption of 
preventive measures in Brazil,
- Prevention and prophylaxis alternatives for preterm 
infants.
Conclusion
Considering the first proposition and the 
unprecedented nature of this study in evaluating the 
effectiveness of the screening strategies for GBS and 
the impact on reducing the incidence of neonatal sepsis, 
the superiority was clear of the universal screening 
strategy for the detection of GBS in sufficient time for 
the adoption of prophylactic measures.
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